423Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Italy
Neuroscience Intelligence
Italy neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #7 of 50 · Data maturity A · Research score 50.4 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
133Recruiting trials
849Publications
323Institutions
Executive interpretation
Italy ranks #7 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC2413 recruiting
Hoffmann-La Roche216 recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS133 recruiting
IRCCS San Raffaele83 recruiting
IRCCS Eugenio Medea83 recruiting
Novartis Pharmaceuticals82 recruiting
Istituto per la Ricerca e l'Innovazione Biomedica83 recruiting
Boehringer Ingelheim70 recruiting
Fondazione Don Carlo Gnocchi ETS73 recruiting
IRCCS Centro Neurolesi Bonino Pulejo74 recruiting
Disease activity
Parkinsons100trials
Alzheimers59trials
Epilepsy54trials
Stroke28trials
Other Neurology27trials
Autism25trials
Multiple Sclerosis20trials
Neuromuscular19trials
Depression16trials
Migraine Headache9trials
Research institutions
Institute for Complex SystemsOpenAlexlinked institution
Institute of Biomedical TechnologiesOpenAlexlinked institution
Institute of Cognitive Sciences and TechnologiesOpenAlexlinked institution
Humanitas GavazzeniOpenAlexlinked institution
Eurac ResearchOpenAlexlinked institution
Istituto di Biomedicina e di Immunologia Molecolare Alberto MonroyOpenAlexlinked institution
Ospedale di MiranoOpenAlexlinked institution
Istituto Dermopatico dell'ImmacolataOpenAlexlinked institution
National Enterprise for NanoScience and NanoTechnologyOpenAlexlinked institution
National Centre for Disease Prevention and ControlOpenAlexlinked institution
Clinical evidence trail
NCT07798674TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasRECRUITING
NCT07761936Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor FluctuationsRECRUITING
NCT07732933Testing a New Gold Nanoparticle-Based Lithium Delivery Method for Bipolar Disorder in Laboratory ModelsNOT_YET_RECRUITING
NCT07533084Italian Validation of the dNA Scale and Its Correlation With Neurocognitive VariablesNOT_YET_RECRUITING
NCT07502066Clinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological DiseasesACTIVE_NOT_RECRUITING
NCT07485218Multidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's DiseaseACTIVE_NOT_RECRUITING
NCT07479914Art of Memory for Cognitive Enhancement in the Monza Brain Health ServiceACTIVE_NOT_RECRUITING
NCT07474779Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and NeuroimagingNOT_YET_RECRUITING
Research evidence trail
PUBMEDBis(monoacylglycero)phosphate (BMP) as a circulating biomarker of lysosomal dysfunction in GNE myopathy.2027-02-15
PUBMEDMicrofluidic confinement enables monitoring of oligomeric forms of 1-40 β-amyloid peptide in kinetic study by AFM.2027-02-01
PUBMEDFrom protection to progression: How CCT/TRiC shapes therapy-induced senescence in glioblastoma multiforme.2027-01-01
PUBMEDMapping reproducible brain-based depression stratification across clinical, cognitive, and neurotransmitter dimensions.2027-01-01
PUBMEDContinuous estetrol/drospirenone regimen for the treatment of endometriosis-related pain: preliminary results.2026-12-31
PUBMEDPredicting early psychiatric readmission among people with major depressive disorder: A machine learning analysis from the prospective multicentre DEEP READ study.2026-12-15
PUBMEDIn memory of Professor Jules Angst: A historian of illness course, a cartographer of bipolarity, and a giant of clinical psychiatry.2026-12-15
PUBMEDMDMA administration reduces ethanol drinking and is associated with altered nociceptin and dynorphin system gene expression in alcohol-preferring rats.2026-12-15
PUBMEDAptamer-guided delivery of miR-126 suppresses glioblastoma stem-like cell invasion and tumor progression.2026-12-08
PUBMEDExpanding the clinical and molecular spectrum of SETD5, NEDD4L, and TBL1X related disorders: A case report and literature review.2026-12-05
PUBMEDPsychopathological Severity Across the Cognitive Continuum: A Comparative Study of Adolescents with Average Intelligence, Borderline Intellectual Functioning, and Intellectual Disability.2026-12-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.